» Authors » Edith E Schermer

Edith E Schermer

Explore the profile of Edith E Schermer including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 13
Citations 1183
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Moral-Sanchez I, Wee E, Xian Y, Lee W, Allen J, Torrents de la Pena A, et al.
NPJ Vaccines . 2024 Apr; 9(1):74. PMID: 38582771
Recombinant native-like HIV-1 envelope glycoprotein (Env) trimers are used in candidate vaccines aimed at inducing broadly neutralizing antibodies. While state-of-the-art SOSIP or single-chain Env designs can be expressed as native-like...
2.
Martin G, Russell R, Mundsperger P, Harris S, Jovanoska L, Trajano L, et al.
NPJ Vaccines . 2023 Jul; 8(1):101. PMID: 37443366
Chemical cross-linking is used to stabilize protein structures with additional benefits of pathogen and toxin inactivation for vaccine use, but its use has been restricted by the potential for local...
3.
Schermer E, Engelfriet P, Blokstra A, Verschuren W, Picavet H
Front Public Health . 2022 Sep; 10:966155. PMID: 36159268
For five health-related lifestyle factors (physical activity, weight, smoking, sleep, and alcohol consumption) we describe both population trends and individual changes over a period of 30 years in the same...
4.
Moral-Sanchez I, Russell R, Schermer E, Cottrell C, Allen J, Torrents de la Pena A, et al.
NPJ Vaccines . 2022 Mar; 7(1):27. PMID: 35228534
Soluble HIV-1 envelope glycoprotein (Env) immunogens are a prime constituent of candidate vaccines designed to induce broadly neutralizing antibodies. Several lines of evidence suggest that enhancing Env immunogen thermostability can...
5.
Schorcht A, Cottrell C, Pugach P, Ringe R, Han A, Allen J, et al.
J Virol . 2021 Oct; 96(1):e0155221. PMID: 34669426
The human immunodeficiency virus type 1 (HIV-1) trimeric envelope glycoprotein (Env) is heavily glycosylated, creating a dense glycan shield that protects the underlying peptidic surface from antibody recognition. The absence...
6.
Brouwer P, Brinkkemper M, Maisonnasse P, Dereuddre-Bosquet N, Grobben M, Claireaux M, et al.
Cell . 2021 Feb; 184(5):1188-1200.e19. PMID: 33577765
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic is continuing to disrupt personal lives, global healthcare systems, and economies. Hence, there is an urgent need for a vaccine that...
7.
van der Velden Y, Villaudy J, Rijnstra E, van der Linden C, Vink M, Schermer E, et al.
MAbs . 2020 Nov; 12(1):1845908. PMID: 33218286
Recent studies have shown the potential of broadly neutralizing antibodies (bnAbs) for HIV-1 treatment. One of the candidate antibodies moving into clinical trials is the bnAb PGDM1400. Here, we studied...
8.
Schorcht A, van den Kerkhof T, Cottrell C, Allen J, Torres J, Behrens A, et al.
J Virol . 2020 Oct; 94(24). PMID: 32999024
The induction of broadly neutralizing antibodies (bNAbs) is a major goal in vaccine research. HIV-1-infected individuals that develop exceptionally strong bNAb responses, termed elite neutralizers, can inform vaccine design by...
9.
Brouwer P, Caniels T, van der Straten K, Snitselaar J, Aldon Y, Bangaru S, et al.
Science . 2020 Jun; 369(6504):643-650. PMID: 32540902
The rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has had a large impact on global health, travel, and economy. Therefore, preventative and therapeutic measures are urgently needed....
10.
Torrents de la Pena A, de Taeye S, Sliepen K, LaBranche C, Burger J, Schermer E, et al.
J Virol . 2018 Jan; 92(8). PMID: 29367243
Recombinant soluble HIV-1 envelope glycoprotein (Env) SOSIP trimers are a design platform for inducing broadly neutralizing antibodies (bNAbs) by vaccination. To date, these and alternative designs of native-like trimers, given...